Top

Published in:

01-06-2013 | Original Paper

Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase

Author: Arthur J. L. Cooper

Published in: Metabolic Brain Disease | Issue 2/2013

Abstract

Glutamine synthetase (GS) is highly active in astrocytes, and these cells are physiologically and morphologically compromised by hyperammonemia. Hyperammonemia in end-stage acute liver failure (ALF) is often associated with cerebral edema and astrocyte pathology/swelling. Many studies of animal models of hyperammonemia, and, more recently, nuclear magnetic resonance studies of liver disease patients, have shown that cerebral glutamine is elevated in hyperammonemia, contributing to the edema and encephalopathy. The GS inhibitor L-methionine-S,R-sulfoximine (MSO) is protective in animal models against acute ammonia intoxication. MSO is also an inhibitor of glutamate cysteine ligase, is converted to metabolic products, and causes convulsions at high doses. However, the susceptibility to MSO-induced convulsions is species dependent, with primates being relatively resistant. Moreover, it is possible to chronically maintain cerebral GS activity in mice at low levels by MSO treatment without any obvious untoward effects. Furthermore, MSO is protective in a mouse model of ALF. Extreme caution would be needed in administering MSO to patients. Nevertheless, inhibition of brain GS by MSO (or other GS inhibitors) may have therapeutic benefit in ALF.

Ammonia free base (NH₃) has a pK _a of ~9.2. Thus, under normal intracellular physiological conditions (pH 7.2 – 7.4) ammonia exists predominantly (~99 %) as the conjugate acid, ammonium (NH ₄ ⁺ ). For convenience, ammonia is used throughout the text to indicate the sum of NH₃ plus NH ₄ ⁺ .

Commercially available MSO exists as a pair of diastereoisomers (L,S and L,R). The L,S diastereoisomer is a potent GS inhibitor, whereas the L,R diastereoisomer is not (Rowe and Meister 1970). In some studies, as noted in the text, a mixture of D,L-methionine-S,R-sulfoximine isomers was used.

Bentley HR, McDermott EE, Whitehead JK (1951) Action of nitrogen trichloride on certain proteins. II. Synthesis of methionine sulphoximine and other sulphoximines. Proc R Soc Lond B Biol Sci 138(891):265–272PubMedCrossRef

Blin M, Crusio WE, Hévor T, Cloix J-F (2002) Chronic inhibition of glutamine synthetase is not associated with impairment of learning and memory in mice. Brain Res Bull 57:11–15PubMedCrossRef

Brosnan ME, Brosnan JT (2009) Hepatic glutamate metabolism: a tale of 2 hepatocytes. Am J Clin Nutr 90:857S–861SPubMedCrossRef

Brusilow SW, Koehler RC, Traystman RJ, Cooper AJL (2010) Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy. Neurotherapeutics 7:452–470PubMedCrossRef

Chatauret N, Desjardins P, Zwingmann C, Rose C, Rao KV, Butterworth RF (2006) Direct molecular and spectroscopic evidence for increased ammonia removal capacity of skeletal muscle in acute liver failure. J Hepatol 44:1083–1088PubMedCrossRef

Chavarria L, Alonso J, Rovira A, Córdoba J (2011) Neuroimaging in acute liver failure. Neurochem Int 59:1175–1180PubMedCrossRef

Cooper AJL (2012) The role of glutamine synthetase and glutamate dehydrogenase in cerebral ammonia homeostasis. Neurochem Res. [Epub ahead of print]

Cooper AJL, Plum F (1987) Biochemistry and physiology of brain ammonia. Physiol Rev 67:440–519PubMed

Cooper AJL, Stephani RA, Meister A (1976) Enzymatic reactions of methionine sulfoximine. Conversion to the corresponding α-imino and α-keto acids and to α-ketobutyrate and methane sulfinimide. J Biol Chem 251:6674–6682PubMed

Cooper AJL, McDonald JM, Gelbard AS, Gledhill RF, Duffy TE (1979) The metabolic fate of ¹³N-labeled ammonia in rat brain. J Biol Chem 254:4982–4992PubMed

Cooper AJL, Vergara F, Duffy TE (1983) Cerebral glutamine metabolism. In: Hertz L, Kvamme E, McGeer EG, Schousboe A (eds) Glutamine, glutamate and GABA in the central nervous system. Alan R Liss, Inc, New York, pp 77–93

Cooper AJL, Mora SN, Cruz NF, Gelbard AS (1985) Cerebral ammonia metabolism in hyperammonemic rats. J Neurochem 44:1716–1723PubMedCrossRef

Desjardins P, Du T, Jiang W, Peng L, Butterworth RF (2012) Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: Role of glutamine redefined. Neurochem Int 60:690–696PubMedCrossRef

Duarte JMN, Lanz B, Gruetter R (2011) Compartmentalised cerebral metabolism of [1,6-¹³C]glucose determined by in vivo ¹³C NMR spectroscopy at 14.1T. Front Neuroenergetics 3:3PubMedCrossRef

Folbergrová J, Passonneau JV, Lowry OH, Schulz DW (1969) Glycogen, ammonia and related metabolities in the brain during seizures evoked by methionine sulphoximine. J Neurochem 16:191–203PubMedCrossRef

Gershoff SN, Elvehjem CA (1951) The relative effect of methionine sulfoximine on different animal species. J Nutr 45:451–458PubMed

Griffith OW, Meister A (1978) Differential inhibition of glutamine and γ-glutamylcysteine synthetases by α-alkyl analogs of methionine sulfoximine that induce convulsions. J Biol Chem 253:2333–2338PubMed

Griffith OW, Meister A (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254:7558–7560PubMed

Hawkins RA, Jessy J, Mans AM, De Joseph MR (1993) Effect of reducing brain glutamine synthesis on metabolic symptoms of hepatic encephalopathy. J Neurochem 60:1000–1006PubMedCrossRef

Jambekar AA, Palma E, Nicolosi L, Rasola A, Petronilli V, Chiara F, Bernardi P, Needleman R, Brusilow WS (2011) A glutamine synthetase inhibitor increases survival and decreases cytokine response in a mouse model of acute liver failure. Liver Int 31:1209–1221PubMedCrossRef

Keiding S, Sørensen M, Bender D, Munk OL, Ott P, Vilstrup H (2006) Brain metabolism of ¹³N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 43:42–50PubMedCrossRef

Krakoff IH (1961) Effect of methionine sulfoximine in man. Clin Pharmacol Ther 2:599–604PubMed

Mans AM, Saunders SJ, Kirsch RE, Biebuyck JF (1979) Correlation of plasma and brain amino acid and putative neurotransmitter alterations during acute hepatic coma in the rat. J Neurochem 32:285–292PubMedCrossRef

Mans AM, DeJoseph MR, Hawkins RA (1994) Metabolic abnormalities and grade of encephalopathy in acute hepatic failure. J Neurochem 63:1829–1838PubMedCrossRef

Meister A (1980) Catalytic mechanism of glutamine synthetase; overview of glutamine metabolism. In: Mora J, Palacios R (eds) Glutamine metabolism, enzymology, and regulation. Academic Press, New York, pp 1–40

Mellanby E (1946) Diet and canine hysteria; experimental production by treated flour. Br Med J 2(4484):885–887PubMedCrossRef

Newell GW, Erickson TC, Gilson WE, Gershoff SN, Elvehjem CA (1949) Studies on human subjects receiving highly agenized food materials. J Lab Clin Med 34:239–245PubMed

Norenberg MD, Martinez-Hernandez A (1979) Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res 161:303–310PubMedCrossRef

Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, Arroliga AC, Mullen KD (2003) Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 114:188–193PubMedCrossRef

Pace J, McDermott E (1952) Methionine sulphoximine and some enzyme systems involving glutamine. Nature 169:415–416PubMedCrossRef

Pamiljans V, Krishnaswamy PR, Dumville G, Meister A (1962) Studies on the mechanism of glutamine synthesis; Isolation and properties of the enzyme from sheep brain. Biochemistry 1:153–158PubMedCrossRef

Pollock GH (1949) Species specificity of agene toxicity. J Appl Physiol 1:802–806PubMed

Pontén U, Ratcheson RA, Salford LG, Siesjö BK (1973) Optimal freezing conditions for cerebral metabolites in rats. J Neurochem 21:1127–1138PubMedCrossRef

Rowe WB, Meister A (1970) Identification of L-methionine-S-sulfoximine as the convulsant isomer of methionine sulfoximine. Proc Natl Acad Sci U S A 66:500–506PubMedCrossRef

Sellinger OZ, Weliler P Jr (1963) the nature of the inhibition in vitro of cerebral glutamine synthetase by the convulsant, methionine sulfoximine. Biochem Pharmacol 12:989–1000PubMedCrossRef

Sellinger OZ, Schatz RA, Gregor P (1986) Cerebral methylations in epileptogenesis. Adv Neurol 44:465–473PubMed

Sibson NR, Mason GF, Shen J, Cline GW, Herskovits AZ, Wall JE, Behar KL, Rothman DL, Shulman RG (2001) In vivo ¹³C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during [2-¹³C]glucose infusion. J Neurochem 76:975–989PubMedCrossRef

Veech RL, Harris RL, Veloso D, Veech EH (1973) Freeze-blowing: a new technique for the study of brain in vivo. J Neurochem 20:183–188PubMedCrossRef

Warren KS, Schenker S (1964) Effect of an inhibitor of glutamine synthesis (methionine sulfoximine) on ammonia toxicity and metabolism. J Lab Clin Med 64:442–449PubMed

Title: Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase
Author: Arthur J. L. Cooper
Publication date: 01-06-2013
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 2/2013
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-012-9338-2

At a glance: The STEP trials

Springer Medicine

Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Hepatic encephalopathy: an enigma from patient to enzyme and back

Disaccharides in the treatment of hepatic encephalopathy

Antibiotics for the treatment of hepatic encephalopathy

Urea cycle defects and hyperammonemia: effects on functional imaging

Psychometric tests for diagnosing minimal hepatic encephalopathy

Update on cerebral uptake of blood ammonia